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Abstract
Our understanding of many aspects of cancer biology has been
advanced through the use of modern genetics. These studies have
already shown that germ line polymorphisms play a significant role
in disease initiation and response to therapy. However, what is less
well studied is the role of germ line polymorphisms in cancer
progression. Studies in rodents indicate that differential suscepti-
bility to cancer metastasis can be heritable; thus, the search for the
genes that control cancer metastasis is underway. Although some
provocative studies suggest potential candidates for metastasis
regulating genes, the conclusive identification of a specific
inherited genetic variant that alters metastatic potential awaits
further studies.
Modern genetics has been applied to many aspects of breast
cancer. For example, it is well established that inherited
mutations in BCRA1 and BCRA2 can predispose women to
this disease, as well as to ovarian cancer [1]. Changes in
other genes, such as p53, PTEN, or CHEK2, are also
associated with increased risk of breast cancer. Recent
genome-wide association studies have led to the
identification of numerous polymorphisms associated with
increased risk for breast cancer, with FGFR2 being one of
the top candidate genes [2,3]. Also, numerous ongoing
studies are being carried out to understand whether there is a
heritable genetic contribution to therapeutic responses in
breast cancer patients [4]. Because of the importance of
metastasis in the prognosis of breast cancer patients, it is
important to determine whether germ line polymorphisms also
play a role in breast cancer metastasis. Indeed, there is a
paucity of data from microarray and other studies to fully
explain breast cancer metastasis from tumor somatic cell
evolution, thus opening the question of whether germline
polymorphisms could contribute to breast cancer metastasis.
Recent studies in mice indicate that inherited genetic
backgrounds can influence metastatic potential. The elucida-
tion of the causal genetic variants in these models may lead
to the identification of important metastasis genes and
heritable genetic variants that predispose humans to breast
cancer metastasis. Using the MMTV-PyMT transgenic mouse
model, which develops mammary tumors with 100%
penetrance, Hunter and colleagues [5] have shown that the
incidence of pulmonary metastasis was influenced by the
mouse genetic background. They found that the AKR and
FVB stains show high metastatic efficiency, while two others
(DBA and NZB) show low rates of metastasis. Quantitative
trait genetic mapping analysis identified a probable
metastasis efficiency locus (Mtes1) on mouse chromosome
19 in a 10 Mb region orthologous to human chromosome
11q12-13. Although the known metastasis suppressor gene
Brms1 maps to this locus, extensive sequencing efforts failed
to identify any genetic polymorphisms. Therefore, a multiple
cross-mapping strategy was used to narrow down the
number of candidate genes to 23 with known molecular
function for further characterization. One of these genes,
Sipa1 (signal-induced proliferation-associated gene 1), was
found to have a non-synonymous single nucleotide poly-
morphism (SNP) in a functional domain. It was, therefore,
considered to be the top candidate for the metastasis
modifier locus Mtes1.
Sipa1 is a mitogen-inducible GTPase-activating protein that
has previously been shown to regulate cell adhesion [6]. Park
and colleagues [5] found that the Sipa1 genes of the highly
metastatic mouse strains AKR and FVB contain a A739T
SNP. This SNP changes a predicted amino acid from an
alanine to threonine in the PDZ protein-protein interaction
domain. In the COS7 and U373MG non-breast cancer cell
lines, functional studies showed that the Thr allele was
associated with reduced concentrations of active, GTP-
bound Rap1. This was due to a weaker interaction between
the 739Thr Sipa1 protein with its inhibitor, AQP2, and,
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consequently, less inhibition of Sipa1 activity. Furthermore,
they showed that altered Sipa1 expression levels resulted in
altered pulmonary metastases.
Although this evidence is consistent with Sipa1 being a
metastasis susceptibility gene, one could argue that these
data are not sufficient to conclude for certain that the Sipa1
polymorphism is a “constitutional genetic polymorphism
affecting tumor metastasis” [5]. To our knowledge, there is no
evidence that the A739T polymorphism affects Sipa1 protein
levels in living cells; however, functional studies in cells
looking at the effect of the SNP were done using cells with
different Sipa1 protein levels, and not with cells harboring
wild-type or variant Sipa1. The generation of appropriate cell
line models for the testing of phenotypes from wild-type and
variant genes is clearly a critical challenge in the SNP field,
not limited to the here discussed Sipa1 study.
An analysis of the online Oncomine tumor gene expression
database [http://www.oncomine.org] showed that Sipa1 was
more highly expressed in metastatic compared to primary
prostate cancers, although there was no difference in
expression between primary breast cancer and metastases.
In any case, since the Oncomine database contains only
expression levels and not genetic variant statuses, the data in
the prostate tumors support the hypothesis that Sipa1
expression levels are associated with metastatic potential, but
can not contribute to our knowledge about the role of Sipa1
genetic variants.
To expand on these exciting findings, Crawford and
colleagues [7] conducted a case control study to specifically
determine whether there is an association between Sipa1
genetic variants and human breast cancer metastasis. Three
SNPs in the Sipa1 gene from the NCBI dbSNP database
(G313A, C545T, and G2760A; http://www.ncbi.nlm.nih.gov/
SNP) were genotyped in a case/control study, in which the
‘controls’ were localized disease (small, well differentiated
tumors; n = 146), and the ‘cases’ were patients with regional
or metastatic disease in which the disease had extended to
skin, muscle, chest wall, lymph nodes, or beyond (n = 154).
There was no significant difference in SNP frequency
between cases and controls, although significant associa-
tions between the G313A and G2760A SNPs and positive
lymph nodes were observed, and the C545T allele correlated
with estrogen receptor/progesterone receptor negative
disease. These studies provide encouraging support for a
role of Sipa1 genetic polymorphisms in breast cancer meta-
stasis; however, two important questions remain from this
study. First, since studies of multiple SNPs and multiple
phenotypes create the potential for multiple comparison
problems and frequent false positive results, it would be
important to either correct for multiple comparisons or know
the predicted false discovery rate. Second, it would be of
interest to determine, through additional sequencing studies,
whether additional SNPs can be identified in the human
Sipa1 PDZ domain, given that this is the functional domain to
which the mouse Sipa1 genetic variant maps. In any case, as
with any genetic association study, replication of these
findings will be key to confirming their role in breast cancer
metastasis.
In conclusion, the hypothesis that germ line polymorphism
can influence human breast cancer metastasis is a
provocative and very exciting new area of research. The
identification of heritable genetic determinants of metastatic
potential could have profound effects on cancer treatments
by improving cancer treatment decisions. For example, more
diligent screening and more aggressive therapies could be
used in patients that are constitutionally more likely to
develop distal relapses. However, this area of research is still
in its infancy. There are many genes known to influence
cancer metastasis and whether inherent genetic variations
can truly affect metastatic potential in patients is not yet
known. The data on the role of Sipa1 are exciting and
address a very important and timely topic. However, as
acknowledged by the authors, “there is no reason to believe
that genes of unknown functions or known genes in pathways
not previously associated with metastasis are not also
potential candidates” [5], and indeed, a second candidate
gene for the Mtes1 locus is already being investigated in the
authors’ laboratory. The scientific community should look
forward to future studies on the role of candidate genes such
as Sipa1 and ‘gene x’ at the Mtes1 locus, as well as to
genome-wide association studies in our search for
polymorphism(s) as breast cancer metastasis modifiers.
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